

Role of P-Glycoprotein in Pharmacokinetics

Clinical Pharmacokinetics

42, 59-98

DOI: 10.2165/00003088-200342010-00003

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. <i>Lancet Neurology</i> , The, 2003, 2, 347-356.	4.9	447
2	Pharmacokinetics for the Prescriber. <i>Medicine</i> , 2003, 31, 11-15.	0.2	3
3	Advances in the Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder: Focus on Methylphenidate Formulations. <i>Pharmacotherapy</i> , 2003, 23, 1281-1299.	1.2	141
4	P-glycoprotein Influences the Brain Concentrations of Cetirizine (Zyrtec®), a Second-Generation Non-Sedating Antihistamine. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 2082-2089.	1.6	76
5	Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 543-554.	2.3	137
6	Clinical Relevance of P-Glycoprotein in Drug Therapy. <i>Drug Metabolism Reviews</i> , 2003, 35, 417-454.	1.5	163
7	Developmental Pharmacology – Drug Disposition, Action, and Therapy in Infants and Children. <i>New England Journal of Medicine</i> , 2003, 349, 1157-1167.	13.9	1,986
8	Classification Analysis of P-Glycoprotein Substrate Specificity. <i>Journal of Drug Targeting</i> , 2003, 11, 391-406.	2.1	228
9	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. <i>Drug Resistance Updates</i> , 2003, 6, 71-84.	6.5	207
10	Drug-Drug, Drug-Dietary Supplement, and Drug-Citrus Fruit and Other Food Interactions: What Have We Learned?. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 559-569.	1.0	127
11	Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2091-2096.	1.4	229
12	Olanzapine Penetration into Brain is Greater in Transgenic Abcb1a P-glycoprotein-Deficient Mice than FVB1 (Wild-Type) Animals. <i>Neuropsychopharmacology</i> , 2004, 29, 551-557.	2.8	82
13	Transient Ischemic Attack Reported with Paroxetine Use. <i>Annals of Pharmacotherapy</i> , 2004, 38, 617-620.	0.9	9
14	Acute Colchicine Intoxication During Clarithromycin Administration. <i>Annals of Pharmacotherapy</i> , 2004, 38, 2074-2077.	0.9	71
15	The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 600-610.	1.1	89
16	Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 399-411.	1.0	124
17	Functional interaction of intestinal CYP3A4 and P-glycoprotein. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 621-626.	1.0	108
18	The role of the medicinal chemist in drug discovery – then and now. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 853-862.	21.5	286

#	ARTICLE	IF	CITATIONS
19	Identification of Budesonide and Prednisone as Substrates of the Intestinal Drug Efflux Pump P-glycoprotein. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 578-583.	0.9	78
20	The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. <i>Journal of Controlled Release</i> , 2004, 95, 447-453.	4.8	249
21	P-glycoprotein expression and distribution in the rat placenta during pregnancy. <i>Reproductive Toxicology</i> , 2004, 18, 785-792.	1.3	63
22	Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?. <i>Biochemical Pharmacology</i> , 2004, 68, 783-790.	2.0	77
23	Predicting P-Glycoprotein Effects on Oral Absorption: Correlation of Transport in Caco-2 with Drug Pharmacokinetics in Wild-Type and <i>mdr1a(-/-)</i> Mice in Vivo. <i>Pharmaceutical Research</i> , 2004, 21, 819-826.	1.7	62
24	Screening of the Interaction Between Xenobiotic Transporters and PDZ Proteins. <i>Pharmaceutical Research</i> , 2004, 21, 1886-1894.	1.7	71
25	VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES. <i>Drug Metabolism and Disposition</i> , 2004, 32, 647-660.	1.7	484
26	Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 153-60.	1.1	16
27	Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood?brain barrier of <i>Abcb1a</i> gene knockout mice. <i>Psychopharmacology</i> , 2004, 173, 132-138.	1.5	98
28	P-glycoprotein function in the elderly. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 97-102.	0.8	52
29	Drug interactions among the antiretrovirals. <i>Current Infectious Disease Reports</i> , 2004, 6, 159-162.	1.3	14
30	Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 957-968.	1.6	100
31	In Vitro absorption and secretory quotients: Practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2567-2572.	1.6	17
32	Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 35, 937-942.	1.4	56
33	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 13-33.	2.3	781
34	Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 172-183.	2.3	230
35	Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 192-200.	2.3	150
36	In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 341-349.	2.3	57

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic Interactions of Drugs with St John's Wort. <i>Journal of Psychopharmacology</i> , 2004, 18, 262-276.	2.0	228
38	Pharmacogenomics of the OATP and OAT families. <i>Pharmacogenomics</i> , 2004, 5, 273-282.	0.6	117
39	Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2004, 43, 623-653.	1.6	708
40	Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids. <i>Clinical Pharmacokinetics</i> , 2004, 43, 741-762.	1.6	102
41	Interactions Between Grapefruit Juice and Cardiovascular Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 281-297.	1.0	188
42	The ABC Transporters MDR1 and MRP2: Multiple Functions in Disposition of Xenobiotics and Drug Resistance. <i>Drug Metabolism Reviews</i> , 2004, 36, 669-701.	1.5	114
43	Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2004, 58, 99-105.	2.0	82
44	Importance of P-glycoprotein at blood-tissue barriers. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 423-429.	4.0	481
45	Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 553-560.	1.9	71
46	Herbal Modulation of P-Glycoprotein. <i>Drug Metabolism Reviews</i> , 2004, 36, 57-104.	1.5	355
47	Natural products and adverse drug interactions. <i>Cmaj</i> , 2004, 170, 1531-1532.	0.9	33
48	Quinidine as a Probe for the Role of P-Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 224-233.	1.0	72
49	Pharmacogenomics of MDR and MRP subfamilies. <i>Personalized Medicine</i> , 2004, 1, 85-104.	0.8	19
50	CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 255-260.	5.7	30
51	Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). <i>Pharmacogenetics and Genomics</i> , 2004, 14, 309-318.	5.7	104
52	Therapeutic Monitoring of Antidepressants in the Era of Pharmacogenetics Studies. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 152-155.	1.0	24
53	Paradoxical Cyclosporine A Requirements in Pediatric Renal Transplants Receiving High-Dose Steroids. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 161-167.	1.0	1
54	Mechanisms of Drug Interactions II. , 2005, , 41-82.		9

#	ARTICLE	IF	CITATIONS
56	A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay. <i>International Journal of Pharmaceutics</i> , 2005, 301, 80-88.	2.6	26
57	Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 17-23.	2.3	133
58	Effect of Grapefruit Juice Volume on the Reduction of Fexofenadine Bioavailability: Possible Role of Organic Anion Transporting Polypeptides*. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 170-177.	2.3	176
59	Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: In vivo evidence of involvement of P-glycoprotein in risperidone disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 43-51.	2.3	62
60	Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the genetic polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 191-201.	2.3	68
61	Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. <i>Pharmacogenomics</i> , 2005, 6, 115-138.	0.6	114
62	Herb-drug interactions: an overview of the clinical evidence. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 1-16.	1.0	197
63	Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. <i>Transplant International</i> , 2005, 18, 140-150.	0.8	60
64	Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 434-437.	1.1	49
65	A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 21-37.	0.7	28
66	Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 267-273.	0.8	18
67	Pharmacokineticâ€“Pharmacodynamic Modeling of the Hydroxy Leresetron Metabolite L6-OH in Rats: An Integrated Parentâ€“Metabolite Model. <i>Pharmaceutical Research</i> , 2005, 22, 1769-1782.	1.7	3
68	Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 103-128.	1.0	36
69	Potentially hazardous drug interactions with psychotropics. <i>Advances in Psychiatric Treatment</i> , 2005, 11, 440-449.	0.6	32
70	EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1220-1228.	1.7	60
71	Ketobemidone is a substrate for cytochrome P450C9 and 3A4, but not for P-glycoprotein. <i>Xenobiotica</i> , 2005, 35, 785-796.	0.5	20
72	Differential Bidirectional Transfer of Indinavir in the Isolated Perfused Human Placenta. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1023-1028.	1.4	43
74	Breast cancer resistance protein in pharmacokinetics and drugâ€“drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 595-611.	1.5	45

#	ARTICLE	IF	CITATIONS
75	Chapter 10 Computational Prediction of ADMET Properties: Recent Developments and Future Challenges. Annual Reports in Computational Chemistry, 2005, 1, 133-151.	0.9	21
76	Evaluation of a novel semi-automated HPLC procedure for whole blood cyclosporin A confirms equivalence to adjusted monoclonal values from Abbott TDx. Clinical Chemistry and Laboratory Medicine, 2005, 43, 228-36.	1.4	4
77	Increased Dose of Lopinavir/Ritonavir Compensates for Efavirenz-Induced Drug-Drug Interaction in HIV-1-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 63-68.	0.9	37
78	Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncology, The, 2005, 6, 780-789.	5.1	107
79	Drug Dosing in Chronic Kidney Disease. Medical Clinics of North America, 2005, 89, 649-687.	1.1	75
80	Drug interactions in the management of HIV infection. Expert Opinion on Pharmacotherapy, 2005, 6, 233-253.	0.9	18
81	Knocking Down Transport: Applications of RNA Interference in The Study of Drug Transport Proteins. Drug Metabolism Reviews, 2005, 37, 705-723.	1.5	12
82	New Horizon of MDR1 (P-glycoprotein) Study. Drug Metabolism Reviews, 2005, 37, 489-510.	1.5	18
83	Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. Drug Metabolism Reviews, 2005, 37, 41-213.	1.5	257
84	Undesirable Effects of Citrus Juice on the Pharmacokinetics of Drugs. Drug Safety, 2005, 28, 677-694.	1.4	93
85	Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs. Clinical Pharmacokinetics, 2005, 44, 279-304.	1.6	419
86	Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals. Clinical Pharmacokinetics, 2005, 44, 849-861.	1.6	51
87	High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-Infected Patients with a Sustained Virological Response on Highly Active Antiretroviral Therapy. Clinical Pharmacokinetics, 2005, 44, 1267-1278.	1.6	16
88	The Influence of Plant Secondary Metabolites on the Nutritional Ecology of Herbivorous Terrestrial Vertebrates. Annual Review of Ecology, Evolution, and Systematics, 2005, 36, 169-189.	3.8	236
89	Recent advances in pharmacokinetic extrapolation from preclinical data to humans. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 583-594.	1.5	5
90	Pharmacokinetics of Methadone. Journal of Pain and Palliative Care Pharmacotherapy, 2005, 19, 13-24.	0.5	152
91	Pharmacokinetic Considerations Relating to Tacrolimus Dosing in the Elderly. Drugs and Aging, 2005, 22, 541-557.	1.3	56
92	High-Throughput Physicochemical and In Vitro ADMET Screening. American Journal of Drug Delivery, 2005, 3, 83-100.	0.6	19

#	ARTICLE	IF	CITATIONS
93	Drugdrug interactions involving membrane transporters in the human kidney. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 505-532.	1.5	71
94	CYTOCHROME P450 GENE INDUCTION IN RATS EX VIVO ASSESSED BY QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (TAQMAN). Drug Metabolism and Disposition, 2006, 34, 1063-1069.	1.7	49
95	LimitedP-glycoprotein mediated efflux for anti-epileptic drugs. Journal of Drug Targeting, 2006, 14, 291-300.	2.1	65
96	CYP3A4 and MDR Mediated Interactions in Drug Therapy. Clinical Research and Regulatory Affairs, 2006, 23, 125-163.	2.1	7
97	Pharmacokinetics: what you need to know. Foundation Years, 2006, 2, 228-232.	0.0	1
98	Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance. Drug Safety, 2006, 29, 735-768.	1.4	89
99	Prediction of Cytochrome P450-Mediated Hepatic Drug Clearance in Neonates, Infants and Children. Clinical Pharmacokinetics, 2006, 45, 1-11.	1.6	103
100	Comparison of Species Differences of P-Glycoproteins in Beagle Dog, Rhesus Monkey, and Human Using ATPase Activity Assays. Molecular Pharmaceutics, 2006, 3, 78-86.	2.3	49
101	A kinetic study of Rhodamine123 pumping by P-glycoprotein. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 1671-1676.	1.4	41
102	Inhibition of the MDR1 transporter by new phenothiazine derivatives. Biochemical and Biophysical Research Communications, 2006, 346, 45-50.	1.0	20
103	MDR- and CYP3A4-mediated drugherbal interactions. Life Sciences, 2006, 78, 2131-2145.	2.0	220
105	Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: Insight into the mechanism of ligand migration and binding sites. Proteins: Structure, Function and Bioinformatics, 2006, 63, 466-478.	1.5	28
106	Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. British Journal of Clinical Pharmacology, 2006, 61, 538-544.	1.1	64
107	Drug interactions in cancer therapy. Nature Reviews Cancer, 2006, 6, 546-558.	12.8	290
108	Drug absorption in the elderly: Biopharmaceutical considerations for the antiepileptic drugs. Epilepsy Research, 2006, 68, 65-69.	0.8	45
109	The complexity of intestinal absorption and exsorption of digoxin in rats. International Journal of Pharmaceutics, 2006, 322, 79-86.	2.6	36
110	Development of an on-line extraction turbulent flow chromatography tandem mass spectrometry method for cassette analysis of Caco-2 cell based bi-directional assay samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 830, 270-277.	1.2	39
111	Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS Journal, 2006, 8, E1-E13.	2.2	219

#	ARTICLE	IF	CITATIONS
112	Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport. <i>Pharmaceutical Research</i> , 2006, 23, 506-512.	1.7	84
113	CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications. <i>Pharmaceutical Research</i> , 2006, 23, 1089-1116.	1.7	242
114	Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1. <i>Pharmaceutical Research</i> , 2006, 23, 1460-1472.	1.7	118
115	Pharmacological Perspectives on the Detoxification of Plant Secondary Metabolites: Implications for Ingestive Behavior of Herbivores. <i>Journal of Chemical Ecology</i> , 2006, 32, 1213-1228.	0.9	73
116	Application of Pharmacological Approaches to Plant-Mammal Interactions. <i>Journal of Chemical Ecology</i> , 2006, 32, 1229-1246.	0.9	42
117	Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): Comparison of rat P-glycoprotein transport to human and mouse. <i>Journal of Pharmacological and Toxicological Methods</i> , 2006, 54, 78-89.	0.3	30
118	Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. <i>Journal of Controlled Release</i> , 2006, 111, 35-40.	4.8	165
119	Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, 110, 135-370.		483
120	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, 112, 184-198.		173
121	Role of P-glycoprotein in Statin Drug Interactions. <i>Pharmacotherapy</i> , 2006, 26, 1601-1607.	1.2	154
122	Telithromycin-Induced Digoxin Toxicity and Electrocardiographic Changes. <i>Pharmacotherapy</i> , 2006, 26, 872-876.	1.2	18
123	Development of a P-Glycoprotein Knockout Model in Rodents to Define Species Differences in its Functional Effect at the Blood-brain Barrier. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 1944-1953.	1.6	40
124	Kinetic Analyses for Species Differences in P-glycoprotein-Mediated Drug Transport. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 2673-2683.	1.6	96
125	Pharmacokinetics and Pharmacokinetic Variability of Heroin and its Metabolites: Review of the Literature. <i>Current Clinical Pharmacology</i> , 2006, 1, 109-118.	0.2	160
126	THE INFLUENCE OF P-GLYCOPROTEIN ON CEREBRAL AND HEPATIC CONCENTRATIONS OF NORTRIPTYLINE AND ITS METABOLITES. <i>Drug Metabolism and Drug Interactions</i> , 2006, 21, 139-162.	0.3	24
127	Lack of Dose-Dependent Effects of Itraconazole on the Pharmacokinetic Interaction with Fexofenadine. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1875-1879.	1.7	28
128	THE ROLE OF THE POLYMORPHIC EFFLUX TRANSPORTER P-GLYCOPROTEIN ON THE BRAIN ACCUMULATION OF d-METHYLPHENIDATE AND d-AMPHETAMINE. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1116-1121.	1.7	19
129	Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. <i>Clinical Microbiology Reviews</i> , 2006, 19, 763-787.	5.7	35

#	ARTICLE	IF	CITATIONS
130	INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION. <i>Drug Metabolism and Disposition</i> , 2006, 34, 775-782.	1.7	34
131	Role of P-glycoprotein in the hepatic metabolism of tacrolimus. <i>Xenobiotica</i> , 2006, 36, 1-13.	0.5	32
132	Cytochrome P450 Enzymes and Drug-Drug Interactions: An Update on the Superfamily. <i>Journal of Pharmacy Technology</i> , 2006, 22, 22-31.	0.5	5
133	Induction of Rat Intestinal P-glycoprotein by Spironolactone and Its Effect on Absorption of Orally Administered Digoxin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 1146-1152.	1.3	28
134	Transporter-mediated drug interactions: clinical implications and in vitro assessment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 81-92.	1.5	83
135	Role of ATP-binding cassette drug transporters in the intestinal absorption of tanshinone IIB, one of the major active diterpenoids from the root of <i>Salvia miltiorrhiza</i> . <i>Xenobiotica</i> , 2007, 37, 375-415.	0.5	23
136	Pharmacokinetics of 1,8-cineole, a dietary toxin, in the brushtail possum (<i>Trichosurus</i>). <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1011-1017.	0.5	36
137	Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of <i>Salvia miltiorrhiza</i> , across the blood-brain barrier. <i>Xenobiotica</i> , 2007, 37, 635-678.	0.5	40
138	Transporter-Mediated Drug Interactions: Molecular Mechanisms and Clinical Implications. , 0, , 159-194.		0
139	Preventing drug interactions with antidepressants in the elderly. <i>Aging Health</i> , 2007, 3, 231-243.	0.3	0
140	Effect of Itraconazole on Pharmacokinetics of Paroxetine: The Role of Gut Transporters. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 45-48.	1.0	32
141	Chapter 29 Computational Models for ADME. <i>Annual Reports in Medicinal Chemistry</i> , 2007, 42, 449-467.	0.5	9
142	Maximising use of <i>in vitro</i> ADMET tools to predict <i>in vivo</i> bioavailability and safety. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 641-665.	1.5	48
143	A Case for Prodrugs. , 2007, , 3-33.		9
144	Prodrug Approaches to Enhancing the Oral Delivery of Poorly Permeable Drugs. , 2007, , 37-82.		5
145	Intestinal permeability and its relevance for absorption and elimination. <i>Xenobiotica</i> , 2007, 37, 1015-1051.	0.5	245
146	The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 315-320.	1.5	22
147	Artificial Membrane Technologies to Assess Transfer and Permeation of Drugs in Drug Discovery. , 2007, , 453-487.		14

#	ARTICLE	IF	CITATIONS
148	The Emerging Importance of Transporter Proteins in the Psychopharmacological Treatment of the Pregnant Patient. <i>Drug Metabolism Reviews</i> , 2007, 39, 723-746.	1.5	27
149	Drug interactions in the management of HIV infection: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2947-2963.	0.9	28
150	In Silico Prediction of Oral Bioavailability. , 2007, , 699-724.		21
151	On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. <i>Xenobiotica</i> , 2007, 37, 1331-1354.	0.5	82
152	Passive Permeability and Active Transport Models for the Prediction of Oral Absorption. , 2007, , 259-278.		8
153	Venlafaxine induces P-glycoprotein in human Caco-2 cells. <i>Human Psychopharmacology</i> , 2007, 22, 49-53.	0.7	31
154	Species Differences of Inhibitory Effects on P-glycoprotein-mediated Drug Transport. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1609-1618.	1.6	61
155	Development of an in silico model for predicting efflux substrates in Caco-2 cells. <i>International Journal of Pharmaceutics</i> , 2007, 343, 98-105.	2.6	17
156	Pharmacogenetics of Opioids. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 429-444.	2.3	298
157	P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2007, 30, 25-31.	0.6	25
158	Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 641-649.	0.7	39
160	Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 376, 135-143.	1.4	10
161	Trabectedin (ET-743, Yondelis [®]) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. <i>Investigational New Drugs</i> , 2007, 25, 1-7.	1.2	18
162	The interactions of flavonoids within neuronal signalling pathways. <i>Genes and Nutrition</i> , 2007, 2, 257-273.	1.2	229
163	Thyroid Hormone Regulates the Expression and Function of P-glycoprotein in Caco-2 Cells. <i>Pharmaceutical Research</i> , 2008, 25, 1037-1042.	1.7	22
164	Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2008, 33, 159-164.	0.6	17
165	The neuroprotective potential of flavonoids: a multiplicity of effects. <i>Genes and Nutrition</i> , 2008, 3, 115-126.	1.2	455
166	Natural health products and cancer chemotherapy and radiation therapy. <i>Oncology Reviews</i> , 2008, 1, 233-242.	0.8	21

#	ARTICLE	IF	CITATIONS
167	Caco-2 Cell methodology and inhibition of the P-glycoprotein transport of digoxin by <i>Aloe vera</i> Juice. <i>Phytotherapy Research</i> , 2008, 22, 1623-1628.	2.8	12
168	Predicting interactions between conventional medications and botanical products on the basis of <i>in vitro</i> investigations. <i>Molecular Nutrition and Food Research</i> , 2008, 52, 747-754.	1.5	24
169	Expression and activity of P-glycoprotein (MDR1/ABCB1) in peripheral blood mononuclear cells from patients with anorexia nervosa compared with healthy controls. <i>International Journal of Eating Disorders</i> , 2008, 41, 432-438.	2.1	5
170	P-gp Inhibition Potential in Cell-Based Models: Which Calculation Method is the Most Accurate?. <i>AAPS Journal</i> , 2008, 10, 577-586.	2.2	47
171	Discovery of Sodium <i>R</i> -(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2 <i>H</i> -pyrimidin-4-yl]ethyl}piperazine-1-carboxylate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7478-7485.	2.9	104
172	<i>In vitro</i> Inhibition of CYP3A4 Metabolism and P-glycoprotein-Mediated Transport by Trade Herbal Products. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 102, 466-475.	1.2	91
173	Expression of MDR1, MRP2 and BCRP mRNA in tissues of turkeys. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2008, 31, 378-385.	0.6	13
174	The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 693-700.	1.1	41
175	Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 27-37.	1.1	89
176	Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 38-46.	1.1	85
177	Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2008, 42, 89-97.	1.5	70
179	The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. <i>Psychiatry Research</i> , 2008, 160, 308-315.	1.7	55
180	MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1439-1444.	2.5	62
181	Splenda Alters Gut Microflora and Increases Intestinal P-Glycoprotein and Cytochrome P-450 in Male Rats. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2008, 71, 1415-1429.	1.1	273
182	In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism. , 2008, , 182-215.		30
183	A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. <i>European Neuropsychopharmacology</i> , 2008, 18, 157-169.	0.3	150
184	Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 721-732.	1.5	82
185	Flavonoids: modulators of brain function?. <i>British Journal of Nutrition</i> , 2008, 99, ES60-ES77.	1.2	302

#	ARTICLE	IF	CITATIONS
186	Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the α_1 -Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4)-Tetrahydroisoquinolin-5-(2-pyridinyl)-5-(2-pyridinyl)-2,3-dihydroquinoline (tetrahydroisoquinolin-5-(2-pyridinyl)-5-(2-pyridinyl)-2,3-dihydroquinoline). <i>Drug Metabolism and Disposition</i> , 2008, 36, 87-94.		12
187	Evaluation of Permeability and P-glycoprotein Interactions: Industry Outlook. , 2008, , 101-138.		4
188	Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neuro-cognitive performance. <i>Proceedings of the Nutrition Society</i> , 2008, 67, 238-252.	0.4	164
189	Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 909-922.	1.5	105
190	Clinically Significant Grapefruit Juice-Drug Interactions. <i>Nutrition Today</i> , 2008, 43, 19-26.	0.6	1
191	Pharmacological Aspects of Neonatal Antidepressant Withdrawal. <i>Obstetrical and Gynecological Survey</i> , 2008, 63, 267-279.	0.2	31
193	Mining Potential Functionally Significant Polymorphisms at the ATP-Binding- Cassette Transporter Genes. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2009, 7, 40-58.	0.2	7
194	Clinically Important Interaction Between Tedisamil and Verapamil. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 560-567.	1.0	4
195	Drug Excretion. , 2009, , 175-199.		12
196	Drug interactions at the blood-brain barrier: Fact or fantasy? . , 2009, 123, 80-104.		173
197	Expert Panel report on a study of Splenda in male rats. <i>Regulatory Toxicology and Pharmacology</i> , 2009, 55, 6-12.	1.3	33
198	Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. <i>Biochemical Pharmacology</i> , 2009, 78, 355-364.	2.0	26
199	In vitro-in vivo correlation in p-glycoprotein mediated transport in intestinal absorption. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 36, 200-211.	1.9	48
200	Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2180-2197.	1.6	44
201	N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a chemical knock-out equivalent to assess the impact of efflux transporters on oral drug absorption in the rat. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4914-4927.	1.6	24
202	Differential Involvement of P-Glycoprotein (ABCB1) in Permeability, Tissue Distribution, and Antinociceptive Activity of Methadone, Buprenorphine, and Diprenorphine: In Vitro and In Vivo Evaluation. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4928-4940.	1.6	75
203	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 183-188.	1.1	30
204	Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells. <i>Phytotherapy Research</i> , 2009, 23, 86-91.	2.8	33

#	ARTICLE	IF	CITATIONS
205	Inhibition of P-glycoprotein function by procyanidine on blood-brain barrier. <i>Phytotherapy Research</i> , 2009, 23, 933-937.	2.8	30
206	Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: Comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions. <i>International Journal of Pharmaceutics</i> , 2009, 375, 48-54.	2.6	24
207	An in vivo microdialysis measurement of harpagoside in rat blood and bile for predicting hepatobiliary excretion and its interaction with cyclosporin A and verapamil. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 751-756.	1.2	8
208	Toward an Increased Understanding of the Barriers to Colonic Drug Absorption in Humans: Implications for Early Controlled Release Candidate Assessment. <i>Molecular Pharmaceutics</i> , 2009, 6, 60-73.	2.3	114
209	The effects of accumulation of an environmentally relevant polychlorinated biphenyl mixture on cytochrome P450 and P-glycoprotein expressions in fetuses and pregnant rats. <i>Chemosphere</i> , 2009, 75, 572-579.	4.2	15
210	Pharmacokinetics and Pharmacodynamic Action of Budesonide after Buccal Administration in Healthy Subjects and Patients with Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 336-343.	2.0	25
211	Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. <i>Schizophrenia Research</i> , 2009, 110, 90-94.	1.1	35
212	Pharmacokinetics and drug metabolism in the elderly. <i>Drug Metabolism Reviews</i> , 2009, 41, 67-76.	1.5	614
213	Budesonide for Crohn's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 971-979.	1.5	17
215	Effects of the P-glycoprotein Inducer Carbamazepine on Fexofenadine Pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 764-768.	1.0	30
216	Clinically significant drug interactions at end of life. <i>Progress in Palliative Care</i> , 2010, 18, 147-156.	0.7	2
217	Pharmacogenetics of Drug Transporters. <i>Current Pharmaceutical Design</i> , 2010, 16, 220-230.	0.9	93
220	Drug Interaction Studies on New Drug Applications: Current Situations and Regulatory Views in Japan. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 3-15.	1.1	17
222	A Quantitative Structure-Activity Relationship for the Modulation Effects of Flavonoids on P-Glycoprotein-Mediated Transport. <i>Chemical and Pharmaceutical Bulletin</i> , 2010, 58, 1187-1194.	0.6	28
223	Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 367-374.	1.2	70
224	Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison withazole antifungal drugs. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 759-764.	1.2	88
225	Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon- β in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 59, 401-408.	1.2	23
226	Elastic-contractile model proteins: Physical chemistry, protein function and drug design and delivery. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 1404-1455.	6.6	49

#	ARTICLE	IF	CITATIONS
227	Pharmacogenetics of Membrane Transporters: An Update on Current Approaches. <i>Molecular Biotechnology</i> , 2010, 44, 152-167.	1.3	103
228	Disposition and toxicity of trabectedin (ET-743) in wild-type and <i>mdr1</i> gene (P-gp) knock-out mice. <i>Investigational New Drugs</i> , 2010, 28, 145-155.	1.2	12
229	L-type calcium channels and psychiatric disorders: A brief review. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1373-1390.	1.1	110
230	Defense mechanisms against toxic phytochemicals in the diet of domestic animals. <i>Molecular Nutrition and Food Research</i> , 2010, 54, 249-258.	1.5	20
231	Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. <i>International Journal of Pharmaceutics</i> , 2010, 396, 127-133.	2.6	10
232	Interactions between Verapamil and Digoxin in Langendorff-Perfused Rat Hearts: The Role of Inhibition of P-glycoprotein in the Heart. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 107, 847-852.	1.2	10
233	Coexistence of passive and carrier-mediated processes in drug transport. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 597-614.	21.5	526
234	Predicting ADME properties in drug discovery. , 2010, , 165-178.		5
235	Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain. <i>Proceedings of the Nutrition Society</i> , 2010, 69, 244-260.	0.4	136
236	P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions. <i>Drug Metabolism and Drug Interactions</i> , 2010, 25, 3-16.	0.3	17
237	Contribution of Intestinal Cytochrome P450-Mediated Metabolism to Drug-Drug Inhibition and Induction Interactions. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 28-47.	1.1	100
238	Expression and Function of P-Glycoprotein in Normal Tissues: Effect on Pharmacokinetics. <i>Methods in Molecular Biology</i> , 2010, 596, 199-222.	0.4	74
239	Characterization of PXR mediated P-glycoprotein regulation in intestinal LS174T cells. <i>Pharmacological Research</i> , 2010, 62, 426-431.	3.1	27
240	Evaluation of In Vivo P-Glycoprotein Phenotyping Probes. <i>Clinical Pharmacokinetics</i> , 2010, 49, 223-237.	1.6	66
241	Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models. <i>Toxicology in Vitro</i> , 2010, 24, 630-637.	1.1	12
242	Clinical significance of ABCB1 genotyping in oncology. <i>Journal of Oncology Pharmacy Practice</i> , 2010, 16, 39-44.	0.5	50
243	Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids. <i>Current Medicinal Chemistry</i> , 2010, 17, 74-95.	1.2	126
244	Homology modeling and binding site assessment of the human P-glycoprotein. <i>Future Medicinal Chemistry</i> , 2011, 3, 297-307.	1.1	17

#	ARTICLE	IF	CITATIONS
245	Development of a Highly Sensitive Method Using Liquid Chromatography-Multiple Reaction Monitoring to Quantify Membrane P-Glycoprotein in Biological Matrices and Relationship to Transport Function. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2440-2449.	1.7	34
246	Inhibitory effects of limonin on six human cytochrome P450 enzymes and P-glycoprotein in vitro. <i>Toxicology in Vitro</i> , 2011, 25, 1828-1833.	1.1	30
247	Neonatal Pharmacology: Extensive Interindividual Variability Despite Limited Size. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2011, 16, 170-184.	0.3	75
248	Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1157-1164.	1.0	93
250	The influence of modulation of P-glycoprotein and/or Cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2011, 34, 417-423.	0.6	7
251	Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 441-449.	1.9	31
252	The Effect of Vitamin D3 and Ketoconazole Combination on VDR-mediated P-gp Expression and Function in Human Colon Adenocarcinoma Cells: Implications in Drug Disposition and Resistance. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 97-102.	1.2	12
253	Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. <i>Pharmacogenomics Journal</i> , 2011, 11, 35-44.	0.9	38
254	Expression of P-Glycoprotein in the Intestinal Epithelium of Dogs with Lymphoplasmacytic Enteritis. <i>Journal of Comparative Pathology</i> , 2011, 145, 199-206.	0.1	12
255	Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. <i>Biochemical Pharmacology</i> , 2011, 81, 244-250.	2.0	20
256	Assessment of P-glycoprotein Activity in the Blood-Brain Barrier (BBB) Using Near Infrared Fluorescence (NIRF) Imaging Techniques. <i>Pharmaceutical Research</i> , 2011, 28, 2505-2515.	1.7	19
257	The effects of PLGA microparticles on intestinal absorption of p-glycoprotein substrate using the everted rat intestinal sac model. <i>Archives of Pharmacal Research</i> , 2011, 34, 1989-1997.	2.7	15
258	Dietary lipids and their oxidized products in Alzheimer's disease. <i>Molecular Nutrition and Food Research</i> , 2011, 55, S161-72.	1.5	41
259	Budesonide in the treatment of inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 419-428.	1.3	36
261	Dabigatran. <i>Hospital Pharmacy</i> , 2011, 46, 196-207.	0.4	1
262	Influence of P-glycoprotein modulation on plasma concentrations and pharmacokinetics of orally administered prednisolone in dogs. <i>American Journal of Veterinary Research</i> , 2012, 73, 900-907.	0.3	13
263	Limitations of In Vitro Assessments of the Drug Interaction Potential of Botanical Supplements. <i>Planta Medica</i> , 2012, 78, 1421-1427.	0.7	31
264	Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 631-639.	1.1	82

#	ARTICLE	IF	CITATIONS
265	Ontogeny of Hepatic Glucuronidation; Methods and Results. <i>Current Drug Metabolism</i> , 2012, 13, 728-743.	0.7	43
266	Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 60, 335-341.	0.8	29
267	Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. <i>Journal of Cardiovascular Pharmacology</i> , 2012, Publish Ahead of Print, .	0.8	32
269	Effects of Ritonavir-Boosted Lopinavir on the Pharmacokinetics of Quinine. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 889-895.	2.3	18
270	An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemiaâ€“reperfusion through distinct mechanisms between CYP3A and P-glycoprotein in the small intestine. <i>European Journal of Pharmacology</i> , 2012, 690, 192-201.	1.7	8
271	Parameters for Pyrethroid Insecticide QSAR and PBPK/PD Models for Human Risk Assessment. <i>Reviews of Environmental Contamination and Toxicology</i> , 2012, 219, 1-114.	0.7	25
272	An update on the ability of St. John's wort to affect the metabolism of other drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 691-708.	1.5	81
273	Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2012, 9, 385-391.	6.1	19
275	Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. <i>Nanotechnology</i> , 2012, 23, 495103.	1.3	39
276	Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. <i>Journal of Drug Targeting</i> , 2012, 20, 736-763.	2.1	99
277	The utility of pharmacokineticâ€“pharmacodynamic modeling in the discovery and optimization of selective S1P ₁ agonists. <i>Xenobiotica</i> , 2012, 42, 671-686.	0.5	10
278	Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 696-706.	2.3	128
279	Devil's Clawâ€“A review of the ethnobotany, phytochemistry and biological activity of <i>Harpagophytum procumbens</i> . <i>Journal of Ethnopharmacology</i> , 2012, 143, 755-771.	2.0	99
280	Interferon-alpha improves docetaxel antitumoral and antimetastatic efficiency in Lewis lung carcinoma bearing mice. <i>Life Sciences</i> , 2012, 91, 843-851.	2.0	3
282	ABCB1 haplotype and OPRM1 118A & G genotype interaction in methadone maintenance treatment pharmacogenetics. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 53.	0.4	39
283	Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs. <i>Pharmacological Reviews</i> , 2012, 64, 722-779.	7.1	185
284	Computational analysis and predictive modeling of polymorph descriptors. <i>Chemistry Central Journal</i> , 2013, 7, 23.	2.6	4
285	Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 327-339.	0.8	24

#	ARTICLE	IF	CITATIONS
286	Acetaminophen Inhibits Intestinal P-Glycoprotein Transport Activity. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3830-3837.	1.6	18
287	A Mechanistic Physiologically Based Pharmacokinetic-Enzyme Turnover Model Involving both Intestine and Liver to Predict CYP3A Induction-Mediated Drug-Drug Interactions. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2819-2836.	1.6	29
288	Proposed mechanistic description of dose-dependent BDE-47 urinary elimination in mice using a physiologically based pharmacokinetic model. <i>Toxicology and Applied Pharmacology</i> , 2013, 273, 335-344.	1.3	9
289	An Open-Label Drug-Drug Interaction Study of the Steady-State Pharmacokinetics of Topiramate and Glyburide in Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2013, 33, 929-938.	1.1	8
290	Sucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2013, 16, 399-451.	2.9	109
291	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. <i>Xenobiotica</i> , 2013, 43, 303-310.	0.5	9
292	Effect of quercetin on P-glycoprotein transport ability in Chinese healthy subjects. <i>European Journal of Clinical Nutrition</i> , 2013, 67, 390-394.	1.3	30
293	Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1463-1472.	1.1	39
294	Correlation-based prediction of tissue-to-plasma partition coefficients using readily available input parameters. <i>Xenobiotica</i> , 2013, 43, 839-852.	0.5	32
295	The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 617-627.	1.5	21
296	Potential Neuroprotective Actions of Dietary Flavonoids. , 2013, , 2617-2640.		1
297	Oral bioavailability of dabigatran etexilate (P[®]radaxa) after co-medication with verapamil in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1053-1062.	1.1	135
298	Pharmacology of the new target-specific oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 133-140.	1.0	39
299	Beneficial Effects of Flavonoids on Neurological Disorders. , 2013, , 83-115.		2
300	Anticoagulation Therapy for Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 147-152.	1.5	16
301	P-glycoprotein Inhibition for Optimal Drug Delivery. <i>Drug Target Insights</i> , 2013, 7, DTI.S12519.	0.9	440
302	Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency. <i>Research and Reports in Urology</i> , 2013, 5, 147.	0.6	5
303	The Roles of Membrane Transporters on the Oral Drug Absorption. <i>Journal of Molecular Pharmaceutics & Organic Process Research</i> , 2013, 1, .	2.0	10

#	ARTICLE	IF	CITATIONS
304	P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives. <i>Current Cancer Drug Targets</i> , 2013, 13, 326-346.	0.8	320
305	Renal Transporters and Biomarkers in Safety Assessment. , 0, , .		4
306	The Role of the Drug Discovery, Clinical, and Regulatory Affairs Teams in Turning a Potent Agent into a Registered Product. , 2014, , .		3
307	Modulation of Cytochrome P450 Metabolism and Transport across Intestinal Epithelial Barrier by GINGER Biophenolics. <i>PLoS ONE</i> , 2014, 9, e108386.	1.1	38
308	In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2). <i>PLoS ONE</i> , 2014, 9, e90689.	1.1	16
309	P-glycoprotein inhibition promotes prednisone retention in human sinonasal polyp explants. <i>International Forum of Allergy and Rhinology</i> , 2014, 4, 734-738.	1.5	14
310	Bioavailability of Tyrosine Kinase Inhibitors: An Added Component of Assessment. <i>Clinical Journal of Oncology Nursing</i> , 2014, 18, 714-716.	0.3	0
311	A novel systems pharmacology model for herbal medicine injection: a case using reduning injection. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 430.	3.7	52
312	Lurasidone drug-drug interaction studies: a comprehensive review. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 191-202.	0.3	29
313	Oral insulin delivery – challenges and strategies. , 2014, , 113-168.		3
314	Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 910-912.	1.1	19
315	Drug transporters in the nasal epithelium: an overview of strategies in targeted drug delivery. <i>Future Medicinal Chemistry</i> , 2014, 6, 1381-1397.	1.1	17
316	Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir. <i>Clinical Drug Investigation</i> , 2014, 34, 173-182.	1.1	52
317	Complementary and Alternative Medicine. <i>Nutrition in Clinical Practice</i> , 2014, 29, 322-331.	1.1	13
318	Coadministration of P-Glycoprotein Modulators on Loperamide Pharmacokinetics and Brain Distribution. <i>Drug Metabolism and Disposition</i> , 2014, 42, 700-706.	1.7	42
319	Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 775-789.	0.8	8
320	The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. <i>Pharmacological Reviews</i> , 2014, 66, 222-307.	7.1	418
321	The ABC gene family in arthropods: Comparative genomics and role in insecticide transport and resistance. <i>Insect Biochemistry and Molecular Biology</i> , 2014, 45, 89-110.	1.2	462

#	ARTICLE	IF	CITATIONS
322	Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model. <i>Photodiagnosis and Photodynamic Therapy</i> , 2014, 11, 603-612.	1.3	24
323	Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia. <i>British Journal of Cancer</i> , 2014, 110, 1673-1680.	2.9	12
324	Interplay of drug metabolizing enzymes with cellular transporters. <i>Wiener Medizinische Wochenschrift</i> , 2014, 164, 461-471.	0.5	3
325	Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 859-871.	1.5	60
326	Suitability of digoxin as a P-glycoprotein probe: Implications of other transporters on sensitivity and specificity. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 3-13.	1.0	28
327	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions. <i>Cancer Treatment Reviews</i> , 2014, 40, 917-926.	3.4	134
328	Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. <i>Chemistry and Biology</i> , 2014, 21, 1115-1142.	6.2	523
329	Absence of P-Glycoprotein Transport in the Pharmacokinetics and Toxicity of the Herbicide Paraquat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 336-345.	1.3	17
330	P-gp modulating drugs greatly potentiate the in vitro effect of ivermectin against resistant larvae of <i>Haemonchus placei</i> . <i>Veterinary Parasitology</i> , 2014, 205, 638-645.	0.7	25
331	Chronic paracetamol treatment increases alterations in cerebral vessels in cortical spreading depression model. <i>Microvascular Research</i> , 2014, 94, 36-46.	1.1	14
332	Association of ABCB1 gene polymorphisms and haplotypes with therapeutic efficacy of glucocorticoids in Chinese patients with immune thrombocytopenia. <i>Human Immunology</i> , 2014, 75, 317-321.	1.2	25
333	Colchicine effect on P-glycoprotein expression and activity: In silico and in vitro studies. <i>Chemico-Biological Interactions</i> , 2014, 218, 50-62.	1.7	33
334	In Vitro Inhibitory Effects of Scutellarin on Six Human/Rat Cytochrome P450 Enzymes and P-glycoprotein. <i>Molecules</i> , 2014, 19, 5748-5760.	1.7	16
335	Tissue distribution of naringenin conjugated metabolites following repeated dosing of naringin to		

#	ARTICLE	IF	CITATIONS
342	Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21 β -Methylmelianodiol in Lung Cancer Cells. PLoS ONE, 2015, 10, e0127841.	1.1	24
343	The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 117-125.	1.2	20
344	Fructose-induced metabolic syndrome decreases protein expression and activity of intestinal P-glycoprotein. Nutrition, 2015, 31, 871-876.	1.1	11
345	The P-glycoprotein inhibitory effect and related mechanisms of thiolated chitosan and its S-protected derivative. RSC Advances, 2015, 5, 104228-104238.	1.7	9
346	Transport of digoxin-loaded polymeric nanoparticles across BeWo cells, an <i>in vitro</i> model of human placental trophoblast. Therapeutic Delivery, 2015, 6, 1325-1334.	1.2	22
347	Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. Journal of Pharmaceutical Sciences, 2015, 104, 4417-4426.	1.6	53
348	Multidrug resistance gene 1 C1236T polymorphism and susceptibility to leukemia: A meta-analysis. Biomedical Reports, 2015, 3, 83-87.	0.9	8
349	Effect of Knockout of Mdr1a and Mdr1b ABCB1 Genes on the Systemic Exposure of a Doxorubicin-Conjugated Block Copolymer in Mice. Molecular Pharmaceutics, 2015, 12, 3175-3183.	2.3	5
350	Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity. Cancer Letters, 2015, 364, 125-134.	3.2	49
351	Deregulation of splicing factors and breast cancer development. Journal of Molecular Cell Biology, 2015, 7, 388-401.	1.5	42
352	Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. British Journal of Clinical Pharmacology, 2015, 80, 1109-1121.	1.1	18
354	P-Glycoprotein Transport of Neurotoxic Pesticides. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 99-107.	1.3	22
355	Computational analysis reveal inhibitory action of nimbin against dengue viral envelope protein. VirusDisease, 2015, 26, 243-254.	1.0	12
356	Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. , 2015, 149, 1-123.		275
357	MDR1 C3435T polymorphism and childhood acute lymphoblastic leukemia susceptibility: An updated meta-analysis. Biomedicine and Pharmacotherapy, 2015, 69, 76-81.	2.5	9
358	Flavonoid compounds as reversal agents of the P-glycoprotein-mediated multidrug resistance: biology, chemistry and pharmacology. Phytochemistry Reviews, 2015, 14, 233-272.	3.1	38
359	The role of MDR1 (C3435T) gene polymorphism in Egyptian acute lymphoblastic leukemia. Comparative Clinical Pathology, 2015, 24, 79-88.	0.3	0
360	Drug-induced cognitive impairment: Effect of cardiovascular agents. Mental Health Clinician, 2016, 6, 201-206.	0.5	26

#	ARTICLE	IF	CITATIONS
361	SYNTHESIS, ANTIPLASMODIAL AND ADMET STUDIES OF 4-METHYLAMINO-2-PHENYLQUINOLINE ANALOGS. International Journal of Pharmacy and Pharmaceutical Sciences, 2016, 8, 173.	0.3	2
362	The Biological Activity of Alkaloids from the Amaryllidaceae: From Cholinesterases Inhibition to Anticancer Activity. Natural Product Communications, 2016, 11, 1934578X1601101.	0.2	18
363	ANTIMICROBIAL AND IN SILICO ADMET SCREENING OF NOVEL (E)-N-(2-(1H-INDOL-3-YL-AMINO)) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 Pharmacy and Pharmaceutical Sciences, 2016, 8, 251.	0.3	11
364	Colchicine-Induced Myopathy in a Tacrolimus-Treated Renal Transplant Recipient. American Journal of Therapeutics, 2016, 23, e614-e616.	0.5	15
365	A Molecular Docking and Dynamics Study to Screen Potent Anti-Staphylococcal Compounds Against Ceftaroline Resistant MRSA. Journal of Cellular Biochemistry, 2016, 117, 542-548.	1.2	13
366	In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate. Clinical Pharmacology in Drug Development, 2016, 5, 364-373.	0.8	3
367	Simultaneous determination of paeoniflorin-6-O-benzene sulfonate (CP-25) and its active paeoniflorin (Pae) metabolite in rat plasma using UPLC-MS/MS: an application for pharmacokinetic studies. RSC Advances, 2016, 6, 113209-113218.	1.7	4
368	Antiproliferative, DNA cleavage, and ADMET study of substituted 2-(1-benzofuran-2-yl) quinoline-4-carboxylic acid and its esters. Cogent Chemistry, 2016, 2, 1158382.	2.5	14
369	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Therapeutic Advances in Endocrinology and Metabolism, 2016, 7, 69-83.	1.4	82
370	Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance. Free Radical Biology and Medicine, 2016, 96, 432-445.	1.3	52
371	Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin. Poultry Science, 2016, 95, 2129-2135.	1.5	12
372	Effects of P-glycoprotein on the intestine and blood-brain barrier transport of YZG-331, a promising sedative-hypnotic compound. European Journal of Pharmacology, 2016, 791, 339-347.	1.7	8
373	Machine learning-, rule- and pharmacophore-based classification on the inhibition of P-glycoprotein and NorA. SAR and QSAR in Environmental Research, 2016, 27, 747-780.	1.0	8
374	Drug Transporters. , 2016, , 91-119.		0
376	Mexican Childhood Acute Lymphoblastic Leukemia: A Pilot Study of the <i>MDR1</i> and <i>MTHFR</i> Gene Polymorphisms and Their Associations with Clinical Outcomes. Genetic Testing and Molecular Biomarkers, 2016, 20, 597-602.	0.3	25
377	Nanostructured lipid carriers: versatile oral delivery vehicle. Future Science OA, 2016, 2, FSO135.	0.9	122
378	Childhood lymphoblastic leukemia adverse drug reactions: study of risk factors and therapy prognosis by optical methods. Proceedings of SPIE, 2016, , .	0.8	1
379	Global marine pollutants inhibit P-glycoprotein: Environmental levels, inhibitory effects, and cocrystal structure. Science Advances, 2016, 2, e1600001.	4.7	96

#	ARTICLE	IF	CITATIONS
380	Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMvbl(P-gp-overexpressing). <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 37.	1.0	3
381	Anti-proliferative and ADMET screening of novel 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives. <i>Cogent Chemistry</i> , 2016, 2, 1172542.	2.5	7
382	The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo. <i>Pharmacology</i> , 2016, 97, 31-37.	0.9	5
383	Opioid Analgesics. , 2016, , 267-301.		2
384	Specific features of pharmacokinetics in children. <i>Drug Metabolism Reviews</i> , 2016, 48, 70-79.	1.5	33
385	Impacts of ABCB1 (G1199A) polymorphism on resistance, uptake, and efflux to steroid drugs. <i>Xenobiotica</i> , 2016, 46, 948-952.	0.5	11
386	Human-Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1). <i>Biochemistry</i> , 2016, 55, 1010-1023.	1.2	14
387	Advances in plant-based inhibitors of P-glycoprotein. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 867-881.	2.5	52
388	Dietary Isoflavones as Modulators of Drug Metabolizing Enzymes and Transporters: Effect on Prescription Medicines. <i>Critical Reviews in Food Science and Nutrition</i> , 2016, 56, S95-S109.	5.4	10
389	Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 485-495.	0.5	15
390	Intracellular concentrations of immunosuppressants. , 2016, , 199-226.		10
391	Large-scale classification of P-glycoprotein inhibitors using SMILES-based descriptors. <i>SAR and QSAR in Environmental Research</i> , 2017, 28, 1-16.	1.0	18
392	Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity. <i>European Journal of Medicinal Chemistry</i> , 2017, 135, 491-516.	2.6	84
393	Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice. <i>Food and Chemical Toxicology</i> , 2017, 107, 68-73.	1.8	9
394	Lipid-Based Nanocarriers in Cancer Therapy. , 2017, , 51-66.		1
395	Antiretroviral therapy in geriatric HIV patients: the GEPO cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2879-2886.	1.3	30
396	The Effect of Verapamil, a Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 548-555.	0.8	22
397	Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 291-303.	0.8	7

#	ARTICLE	IF	CITATIONS
398	Cardiovascular Ion Channel Inhibitor Drug-Drug Interactions with P-glycoprotein. <i>AAPS Journal</i> , 2017, 19, 409-420.	2.2	20
399	On the mechanism of substrate/non-substrate recognition by P-glycoprotein. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 71, 227-232.	1.3	18
400	Toxicological Effects of <i>Glycyrrhiza glabra</i> (Licorice): A Review. <i>Phytotherapy Research</i> , 2017, 31, 1635-1650.	2.8	167
401	Novel synthesis of isoindoline/isoindoline-1,3-dione derivatives under solventless conditions and evaluation with the human D2 receptor. <i>Medicinal Chemistry Research</i> , 2017, 26, 2420-2431.	1.1	11
402	Effect of ketoconazole on the transport and metabolism of drugs in the human liver cell model. <i>Russian Chemical Bulletin</i> , 2017, 66, 150-155.	0.4	5
403	Genome-wide identification of ATP-binding cassette (ABC) transporters and conservation of their xenobiotic transporter function in the monogonont rotifer (<i>Brachionus koreanus</i>). <i>Comparative Biochemistry and Physiology Part D: Genomics and Proteomics</i> , 2017, 21, 17-26.	0.4	12
404	Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 269-293.	1.1	62
405	The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy. <i>Frontiers in Pharmacology</i> , 2016, 7, 535.	1.6	108
406	Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2957-2968.	2.0	12
407	Effects on P-Glycoprotein Expression after Blood-Brain Barrier Disruption Using Focused Ultrasound and Microbubbles. <i>PLoS ONE</i> , 2017, 12, e0166061.	1.1	115
408	SYNTHESIS, ANTIMICROBIAL, ANTITUBERCULAR AND CHEMINFORMATIC STUDIES OF 2-(1-BENZOFURAN-2-YL)-N'-[(3Z)-2-OXO-1, 2-DIHYDRO-3H-INDOL-3-YLIDENE] QUINOLINE-4-CARBOHYDRAZIDE AND ITS DERIVATIVES. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 9, 260.	0.3	8
409	Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP. <i>Molecules</i> , 2017, 22, 600.	1.7	91
410	Preclinical Pharmacology and Toxicology - Contributions to the Translational Interface ., 2017, , .		4
411	Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. <i>Journal of Oncology Practice</i> , 2017, 13, 720-727.	2.5	17
412	IN VITRO ANTIOXIDANT, ANTIMICROBIAL AND ADMET STUDY OF NOVEL FURAN/BENZOFURAN C-2 COUPLED QUINOLINE HYBRIDS. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 9, 144.	0.3	1
413	Mechanisms of Drug Interactions II: Transport Proteins. , 2018, , 49-85.		3
414	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
415	Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1155-1164.	2.3	49

#	ARTICLE	IF	CITATIONS
416	Antiparasitic, structural, pharmacokinetic, and toxicological properties of riparin derivatives. <i>Toxicology in Vitro</i> , 2018, 50, 1-10.	1.1	41
417	A Conformationally Gated Model of Methadone and Loperamide Transport by P-Glycoprotein. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1937-1947.	1.6	10
418	Toxicological effects of <i>Camellia sinensis</i> (green tea): A review. <i>Phytotherapy Research</i> , 2018, 32, 1163-1180.	2.8	88
419	ABCB1 1199G Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics. <i>DNA and Cell Biology</i> , 2018, 37, 325-329.	0.9	9
420	Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 42-50.	1.2	25
421	High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 68-79.	1.9	4
422	P-glycoprotein Restricts Ocular Penetration of Loperamide across the Blood-Ocular Barriers: a Comparative Study in Mdr1a Knock-out and Wild Type Sprague Dawley Rats. <i>AAPS PharmSciTech</i> , 2018, 19, 1662-1671.	1.5	6
423	The Use of Serum Methadone/Metabolite Ratios to Monitor Changing Perinatal Pharmacokinetics. <i>Journal of Addiction Medicine</i> , 2018, 12, 241-246.	1.4	19
424	A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 482-489.	1.1	9
425	Variability in expression of the human MDR1 drug efflux transporter and genetic variation of the ABCB1 gene: implications for drug-resistant epilepsy. <i>Current Opinion in Toxicology</i> , 2018, 11-12, 35-42.	2.6	8
426	Fabrication of Biodegradable Poly(naringin) Particles with Antioxidant Activity and Low Toxicity. <i>ACS Omega</i> , 2018, 3, 17359-17367.	1.6	22
427	Study of New Therapeutic Strategies to Combat Breast Cancer Using Drug Combinations. <i>Biomolecules</i> , 2018, 8, 175.	1.8	31
428	Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. <i>Molecular Pharmaceutics</i> , 2018, 15, 4835-4842.	2.3	42
429	Alterations of drug-metabolizing enzymes and transporters under diabetic conditions: what is the potential clinical significance?. <i>Drug Metabolism Reviews</i> , 2018, 50, 369-397.	1.5	9
430	Identification and analyses of natural compounds as potential inhibitors of TRAF6-Basigin interactions in melanoma using structure-based virtual screening and molecular dynamics simulations. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 85, 281-293.	1.3	5
431	An update on the potential role of intestinal first-pass metabolism for the prediction of drug-drug interactions: the role of PBPK modeling. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 625-634.	1.5	13
432	Interspecies comparison of putative ligand binding sites of human, rat and mouse P-glycoprotein. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 122, 134-143.	1.9	16
433	Design and synthesis of novel 5-(4-chlorophenyl)furan derivatives with inhibitory activity on tubulin polymerization. <i>Future Medicinal Chemistry</i> , 2018, 10, 1907-1924.	1.1	3

#	ARTICLE	IF	CITATIONS
435	Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis. <i>Pharmaceutics</i> , 2018, 10, 66.	2.0	19
436	Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski's Rule of Five. <i>International Journal of Pharmaceutics</i> , 2018, 549, 133-149.	2.6	110
437	High throughput screening against pantothenate synthetase identifies amide inhibitors against <i>Mycobacterium tuberculosis</i> and <i>Staphylococcus aureus</i> . <i>In Silico Pharmacology</i> , 2018, 6, 9.	1.8	5
438	Structure and Function of Multidrug Resistance Protein 1. <i>Biochemistry (Moscow)</i> , 2018, 83, 907-929.	0.7	13
439	Endemic Mycoses in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 667-685.	1.9	19
440	In silico analysis of nsSNPs in ABCB1 gene affecting breast cancer associated protein P-glycoprotein (P-gp). <i>Computational Biology and Chemistry</i> , 2018, 77, 430-441.	1.1	10
441	Discovery of a Piperonal-Entecavir Schiff Base Compound That Overcomes Multidrug Resistance by Inhibiting P-Glycoprotein. <i>Assay and Drug Development Technologies</i> , 2018, 16, 205-211.	0.6	2
442	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 15-37.	1.6	91
443	<i>Streptococcus agalactiae</i> disrupts P-glycoprotein function in brain endothelial cells. <i>Fluids and Barriers of the CNS</i> , 2019, 16, 26.	2.4	18
444	Pharmacogenetics of therapeutics. , 2019, , 41-74.		0
445	Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2351-2359.	1.1	3
446	Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 125, 508-517.	1.2	12
447	Fundamentals of Brain Barrier Anatomy and Global Functions. , 2019, , 3-20.		2
448	Oral delivery of paclitaxel by polymeric micelles: A comparison of different block length on uptake, permeability and oral bioavailability. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 184, 110554.	2.5	24
449	Montmorillonite-surfactant hybrid particles for modulating intestinal P-glycoprotein-mediated transport. <i>International Journal of Pharmaceutics</i> , 2019, 571, 118696.	2.6	11
450	Successful optimization of antiretroviral regimens in treatment-experienced people living with HIV undergoing liver transplantation. <i>Transplant Infectious Disease</i> , 2019, 21, e13174.	0.7	4
451	Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1403-1414.	1.7	13
452	Reversible inhibition of efflux transporters by hydrogel microdevices. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 145, 76-84.	2.0	12

#	ARTICLE	IF	CITATIONS
453	Structure based virtual screening of natural products to disrupt the structural integrity of TRAF6 C-terminal domain homotrimer. <i>Journal of Molecular Graphics and Modelling</i> , 2019, 93, 107428.	1.3	4
454	Evaluation of drug candidature: In silico ADMET, binding interactions with CDK7 and normal cell line studies of potentially anti-breast cancer enamidines. <i>Computational Biology and Chemistry</i> , 2019, 83, 107124.	1.1	6
455	Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24. <i>Computers in Biology and Medicine</i> , 2019, 113, 103414.	3.9	32
456	Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance?. <i>Medical Hypotheses</i> , 2019, 132, 109325.	0.8	15
457	Testosterone and androstenedione are endogenous substrates of P-glycoprotein. <i>Biochemical and Biophysical Research Communications</i> , 2019, 520, 166-170.	1.0	15
458	The effective treatment of multi-drug resistant tumors with self-assembling alginate copolymers. <i>Polymer Chemistry</i> , 2019, 10, 278-286.	1.9	11
459	In silico approaches and tools for the prediction of drug metabolism and fate: A review. <i>Computers in Biology and Medicine</i> , 2019, 106, 54-64.	3.9	76
460	Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption. <i>International Journal of Pharmaceutics</i> , 2019, 566, 410-433.	2.6	40
461	The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 1390-1397.	1.1	26
462	In vitro cell uptake evaluation of curcumin-loaded PCL/F68 nanoparticles for potential application in neuronal diseases. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 52, 905-914.	1.4	33
463	Antidepressant pharmacogenetics in children and young adults: A systematic review. <i>Journal of Affective Disorders</i> , 2019, 254, 98-108.	2.0	27
464	JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 547-554.	1.3	21
465	Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with existing diabetic drugs. <i>Journal of Diabetes and Metabolic Disorders</i> , 2019, 18, 229-242.	0.8	1
466	Crystal Structures of Protein-Bound Cyclic Peptides. <i>Chemical Reviews</i> , 2019, 119, 9861-9914.	23.0	65
467	The role of caveolin-1 in tumors of the brain - functional and clinical implications. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 423-447.	2.1	10
468	Novel phthalamide derivatives as antihypertensive agents: rapid and clean synthesis, in silico and in vivo evaluation. <i>Medicinal Chemistry Research</i> , 2019, 28, 681-695.	1.1	2
469	Examining P-gp efflux kinetics guided by the BDDCS " Rational selection of in vitro assay designs and mathematical models. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 132, 132-141.	1.9	8
470	Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1281-1294.	1.6	98

#	ARTICLE	IF	CITATIONS
471	Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 337-348.	0.7	28
472	Quercetin promotes learning and memory performance concomitantly with neural stem/progenitor cell proliferation and neurogenesis in the adult rat dentate gyrus. <i>International Journal of Developmental Neuroscience</i> , 2019, 74, 18-26.	0.7	54
473	Blocking the catalytic mechanism of MurC ligase enzyme from <i>Acinetobacter baumannii</i> : An in Silico guided study towards the discovery of natural antibiotics. <i>Journal of Molecular Liquids</i> , 2019, 281, 117-133.	2.3	5
474	The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 516-529.	1.1	20
475	Genetics in Forensic Science. <i>Current Human Cell Research and Applications</i> , 2019, , 105-121.	0.1	0
476	Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 488-499.	1.0	2
477	Pharmacology of Oral Anticoagulants. , 2019, , 11-34.		2
478	Formulation and evaluation of itraconazole liposomes for Hedgehog pathway inhibition. <i>Journal of Liposome Research</i> , 2020, 30, 305-311.	1.5	17
479	Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes. <i>Xenobiotica</i> , 2020, 50, 733-740.	0.5	12
480	Design, synthesis and ADMET prediction of bis-benzimidazole as anticancer agent. <i>Bioorganic Chemistry</i> , 2020, 96, 103576.	2.0	71
481	Kinetic analysis of sequential metabolism of triazolam and its extrapolation to humans using an entero-hepatic two-organ microphysiological system. <i>Lab on A Chip</i> , 2020, 20, 537-547.	3.1	25
482	Structural characterization and antioxidant activity of a glycoprotein isolated from <i>Camellia oleifera</i> Abel seeds against D-galactose-induced oxidative stress in mice. <i>Journal of Functional Foods</i> , 2020, 64, 103594.	1.6	22
483	Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 384-392.	0.6	3
484	The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109657.	2.5	7
485	Enhanced antitumor efficacy of bile acid-lipid complex-anchored docetaxel nanoemulsion via oral metronomic scheduling. <i>Journal of Controlled Release</i> , 2020, 328, 368-394.	4.8	18
486	Molecular docking and ADMET study of bioactive compounds of <i>Glycyrrhiza glabra</i> against main protease of SARS-CoV2. <i>Materials Today: Proceedings</i> , 2022, 49, 2999-3007.	0.9	51
487	Moesin-Mediated P-Glycoprotein Activation During Snail-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2302-2308.	1.6	15
488	Equine Drug Transporters: A Mini-Review and Veterinary Perspective. <i>Pharmaceutics</i> , 2020, 12, 1064.	2.0	2

#	ARTICLE	IF	CITATIONS
489	Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs). <i>FEBS Letters</i> , 2020, 594, 4158-4185.	1.3	12
490	Combining Machine Learning and Molecular Dynamics to Predict P-Glycoprotein Substrates. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 4730-4749.	2.5	30
491	Compound Prunetin Induces Cell Death in Gastric Cancer Cell with Potent Anti-Proliferative Properties: In Vitro Assay, Molecular Docking, Dynamics, and ADMET Studies. <i>Biomolecules</i> , 2020, 10, 1086.	1.8	27
492	Structural insight into TNF- α inhibitors through combining pharmacophore-based virtual screening and molecular dynamic simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 5920-5939.	2.0	4
493	Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators. <i>Molecules</i> , 2020, 25, 3364.	1.7	44
494	Novel mannopyranoside esters as sterol 14 α -demethylase inhibitors: Synthesis, PASS prediction, molecular docking, and pharmacokinetic studies. <i>Carbohydrate Research</i> , 2020, 496, 108130.	1.1	22
495	Enhanced oral bioavailability of an etoposide multiple nanoemulsion incorporating a deoxycholic acid derivative-lipid complex. <i>Drug Delivery</i> , 2020, 27, 1501-1513.	2.5	15
496	Theoretical evaluation of EGFR kinase inhibition and toxicity of di-indol-3-yl disulphides with anti-cancer potency. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 622-634.	2.0	4
497	Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study. <i>American Journal of Gastroenterology</i> , 2020, 115, 1513-1524.	0.2	9
498	Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. <i>British Journal of Pharmacology</i> , 2021, 178, 3294-3308.	2.7	9
499	Interactions between antiretroviral therapy and complementary and alternative medicine: a narrative review. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1161-1170.	2.8	20
500	Metabolism and disposition of oseltamivir (OS) in rats, determined by immunohistochemistry with monospecific antibody for OS or its active metabolite oseltamivir carboxylate (OC): A possibility of transporters dividing the drugs' excretion into the bile and kidney. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00597.	1.1	2
501	Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. <i>JAMA Internal Medicine</i> , 2020, 180, 1052.	2.6	33
502	Optimization of an oral mucosa <i>in vitro</i> model based on cell line TR146. <i>Tissue Barriers</i> , 2020, 8, 1748459.	1.6	21
503	Leishmanicidal Potential of Hardwickiiic Acid Isolated From <i>Croton sylvaticus</i> . <i>Frontiers in Pharmacology</i> , 2020, 11, 753.	1.6	16
504	The effect of gender and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female Pakistani subjects. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 506-510.	0.7	6
505	Peripheral Opioid Receptor Antagonists for Opioid-Induced Constipation: A Primer on Pharmacokinetic Variabilities with a Focus on Drug Interactions. <i>Journal of Pain Research</i> , 2020, Volume 13, 447-456.	0.8	3
506	Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 699-714.	1.6	150

#	ARTICLE	IF	CITATIONS
507	The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology, 2020, 80, 106210.	1.7	424
508	Association between polymorphisms in microRNA seed region and warfarin stable dose. Postgraduate Medical Journal, 2020, 96, 737-741.	0.9	1
509	A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. Journal of the International Association of Providers of AIDS Care, 2020, 19, 232595822091923.	0.6	66
510	<p>Engineering of Long-Term Stable Transparent Nanoemulsion Using High-Gravity Rotating Packed Bed for Oral Drug Delivery</p>. International Journal of Nanomedicine, 2020, Volume 15, 2391-2402.	3.3	7
511	Molecular avenues in targeted doxorubicin cancer therapy. Future Oncology, 2020, 16, 687-700.	1.1	28
512	Polymorphisms. , 2021, , 21-33.e2.		5
513	The effects of P-glycoprotein inhibitor zosuquidar on the sex and time-dependent pharmacokinetics of parenterally administered talinolol in mice. European Journal of Pharmaceutical Sciences, 2021, 156, 105589.	1.9	5
514	In vitro evaluation of antitrypanosomal activity and molecular docking of benzoylthioureas. Parasitology International, 2021, 80, 102225.	0.6	8
515	Identification of DNA Methyltransferase-1 Inhibitor for Breast Cancer Therapy through Computational Fragment-Based Drug Design. Molecules, 2021, 26, 375.	1.7	6
516	An integrated virtual screening of compounds from Carica papaya leaves against multiple protein targets of SARS-Coronavirus-2. Results in Chemistry, 2021, 3, 100113.	0.9	11
517	Development of an <i>In Silico</i> Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. Journal of Medicinal Chemistry, 2021, 64, 2725-2738.	2.9	22
518	Antioxidant-Rich Woodfordia fruticosa Leaf Extract Alleviates Depressive-Like Behaviors and Impede Hyperglycemia. Plants, 2021, 10, 287.	1.6	21
519	Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. Pharmacogenomics Journal, 2021, 21, 262-272.	0.9	4
520	Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects. Archives of Toxicology, 2021, 95, 1535-1546.	1.9	24
521	A Molecular Modeling Approach to Identify Potential Antileishmanial Compounds Against the Cell Division Cycle (cdc)-2-Related Kinase 12 (CRK12) Receptor of Leishmania donovani. Biomolecules, 2021, 11, 458.	1.8	19
522	<i>Berberis lyceum</i> and <i>Fumaria indica</i>: <i>inÂvitro</i> cytotoxicity, antioxidant activity, and <i>in silico</i> screening of their selected phytochemicals as novel hepatitis C virus nonstructural protein 5A inhibitors. Journal of Biomolecular Structure and Dynamics, 2022, 40, 7829-7851.	2.0	5
523	Synthesis, antimicrobial, antioxidant, and ADMET studies of quinoline derivatives. European Journal of Chemistry, 2021, 12, 37-44.	0.3	4
524	Network pharmacology based high throughput screening for identification of multi targeted anti-diabetic compound from traditionally used plants. Journal of Biomolecular Structure and Dynamics, 2022, 40, 8004-8017.	2.0	6

#	ARTICLE	IF	CITATIONS
525	Effects of Quercetin and Resveratrol on Zinc Chloride- and Sodium Metavanadate-Induced Passive Avoidance Memory Retention Deficits in Male Mice. <i>Preventive Nutrition and Food Science</i> , 2021, 26, 67-74.	0.7	2
526	Safety Review of Herbs and Supplements in Heart Disease, Diabetes, and COVID-19. , 0, , .		0
528	BENZIMIDAZOLE MOLECULE HYBRID WITH OXADIAZOLE RING AS ANTIPROLIFERATIVE AGENTS: IN-SILICO ANALYSIS, SYNTHESIS AND BIOLOGICAL EVALUATION. <i>Journal of the Chilean Chemical Society</i> , 2021, 66, 5164-5182.	0.5	7
529	E3 Ubiquitin Ligase in Anticancer Drug Resistance: Recent Advances and Future Potential. <i>Frontiers in Pharmacology</i> , 2021, 12, 645864.	1.6	8
530	Novel Indole derivative as first P-glycoprotein inhibitor from the skin of Indian toad (Bufo Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 582 Td (0.6	1
531	Multiple roles of ABC transporters in yeast. <i>Fungal Genetics and Biology</i> , 2021, 150, 103550.	0.9	32
532	Frequency of ABCB1 C3435T and CYP3A5*3 Genetic Polymorphisms in the Lebanese Population. <i>Experimental and Clinical Transplantation</i> , 2021, 19, 434-438.	0.2	1
533	A systematic literature review (SLR): evaluation pharmacokinetic profile of drug combined p-glycoprotein (p-gp) alkaloid inhibitor in white rats (rattus norvegicus). <i>Journal of Physics: Conference Series</i> , 2021, 1912, 012047.	0.3	0
534	Computational Investigation Identified Potential Chemical Scaffolds for Heparanase as Anticancer Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5311.	1.8	12
535	Letâ€™s Talk about Placental Sex, Baby: Understanding Mechanisms That Drive Female- and Male-Specific Fetal Growth and Developmental Outcomes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6386.	1.8	61
536	Deposition of pentamidine analogues in the human body â€™ spectroscopic and computational approaches. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 161, 105779.	1.9	1
537	Pharmacogenomics and Morphine. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1149-1155.	1.0	13
538	COMPUTATIONAL APPROACHES RELATED TO DRUG DISPOSITION. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 19-27.	0.3	5
539	Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective. <i>Computers in Biology and Medicine</i> , 2021, 134, 104406.	3.9	14
540	A metal-free salalen ligand with anti-tumor and synergistic activity in resistant leukemia and solid tumor cells via mitochondrial pathway. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2591-2607.	1.2	6
541	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapiesâ€™ TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2068-2081.	1.9	23
542	Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. <i>Pharmaceutics</i> , 2021, 13, 1103.	2.0	69
543	An in-silico analysis reveals 7,7â€™-bializarin as a promising DNA gyrase B inhibitor on Gram-positive and Gram-negative bacteria. <i>Computers in Biology and Medicine</i> , 2021, 135, 104626.	3.9	8

#	ARTICLE	IF	CITATIONS
544	SARS-CoV-2 host cell entry: an in silico investigation of potential inhibitory roles of terpenoids. <i>Journal of Genetic Engineering and Biotechnology</i> , 2021, 19, 113.	1.5	10
545	Ziziphus oenoplia Mill.: A Systematic Review on Ethnopharmacology, Phytochemistry and Pharmacology of an Important Traditional Medicinal Plant. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 640-660.	1.1	4
546	Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1526-1536.	2.3	38
547	Synthesis, characterization, X-ray, HOMO-LUMO, MEP, FT-IR, NLO, Hirshfeld surface, ADMET, boiled-egg model properties and molecular docking studies with human cyclophilin D (CypD) of a Schiff base compound: (E)-1-(5-nitro-2-(piperidin-1-yl)phenyl)-N-(3-nitrophenyl)methanimine. <i>Polyhedron</i> , 2021, 205, 115320.	1.0	22
548	Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice. <i>British Journal of Pharmacology</i> , 2021, 178, 4335-4351.	2.7	7
549	A study on catalytic and non-catalytic sites of H5N1 and H1N1 neuraminidase as the target for chalcone inhibitors. <i>Applied Biological Chemistry</i> , 2021, 64, 69.	0.7	5
550	Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics. <i>Pharmaceutics</i> , 2021, 13, 1573.	2.0	4
551	Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. <i>AAPS Journal</i> , 2021, 23, 106.	2.2	7
552	Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9815.	1.8	4
553	Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from <i>Vernonia amygdalina</i> and <i>Occinum gratissimum</i> . <i>Computers in Biology and Medicine</i> , 2021, 136, 104671.	3.9	22
554	Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 343-357.	1.3	7
555	Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC). <i>Bioorganic Chemistry</i> , 2021, 115, 105234.	2.0	33
556	Modulation of the transport of valproic acid through the blood-brain barrier in rats by the <i>Gastrodia elata</i> extracts. <i>Journal of Ethnopharmacology</i> , 2021, 278, 114276.	2.0	6
557	Potential bioactive compounds as SARS-CoV-2 inhibitors from extracts of the marine red alga <i>Halymenia durvillei</i> (Rhodophyta) – A computational study. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103393.	2.3	15
558	Chinese ginseng. , 2021, , 853-864.		1
559	Molecular modelling and de novo fragment-based design of potential inhibitors of beta-tubulin gene of <i>Necator americanus</i> from natural products. <i>Informatics in Medicine Unlocked</i> , 2021, 26, 100734.	1.9	4
560	Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials. <i>Cephalalgia Reports</i> , 2021, 4, 251581632110373.	0.2	1
564	Strategic Use of Preclinical Pharmacokinetic Studies and In Vitro Models in Optimizing ADME Properties of Lead Compounds. , 2006, , 1-23.		2

#	ARTICLE	IF	CITATIONS
565	Instrumented In Vitro Approaches to Assess Epithelial Permeability of Drugs from Pharmaceutical Formulations. , 2008, , 430-455.		2
566	Anticipating and Minimizing Drug Interactions in a Drug Discovery and Development Setting: An Industrial Perspective. , 2010, , 585-624.		3
567	Beneficial Effects of Propolis on Neurological Disorders. , 2013, , 301-322.		3
568	Beneficial Effects of Green Tea Catechins on Neurological Disorders. , 2013, , 117-149.		1
569	Pharmacogenetics of Membrane Transporters: A Review of Current Approaches. Methods in Molecular Biology, 2014, 1175, 91-120.	0.4	20
570	Pharmacogenetics of Membrane Transporters. Methods in Molecular Biology, 2008, 448, 41-62.	0.4	21
571	Psychopharmakotherapie â€“ pharmakologische Grundlagen. , 2017, , 749-793.		2
572	Pharmacotherapy for Mood and Anxiety Disorders. Mental Health and Illness Worldwide, 2017, , 427-453.	0.1	1
574	Engineered gene networks enable nonâ€“genetic drug resistance and enhanced cellular robustness. Engineering Biology, 2019, 3, 72-79.	0.8	10
575	Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis. Clinical Infectious Diseases, 2019, 69, 1996-2002.	2.9	11
576	Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?. Medical Science Monitor, 2018, 24, 3136-3145.	0.5	5
577	E. coli Infection Modulates the Pharmacokinetics of Oral Enrofloxacin by Targeting P-Glycoprotein in Small Intestine and CYP450 3A in Liver and Kidney of Broilers. PLoS ONE, 2014, 9, e87781.	1.1	24
578	Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA. PLoS ONE, 2015, 10, e0136396.	1.1	5
579	Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. PLoS ONE, 2015, 10, e0143701.	1.1	21
580	Maximising use of <i>in vitro</i> ADMET tools to predict <i>in vivo</i> bioavailability and safety. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 641-665.	1.5	2
581	Multi-drug resistance gene (MDR1) and opioid analgesia in horses. Ciencia Rural, 2006, 36, 330-335.	0.3	1
582	Emerging Trends in Oral Delivery of Peptide and Protein Drugs. Critical Reviews in Therapeutic Drug Carrier Systems, 2003, 20, 153-214.	1.2	282
583	Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use. Bosnian Journal of Basic Medical Sciences, 2021, 21, 145-154.	0.6	5

#	ARTICLE	IF	CITATIONS
584	Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. <i>Oncotarget</i> , 2015, 6, 17738-17752.	0.8	17
585	Clinically Important Drug-Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2019, 10, 3552-3559.	0.2	9
586	In Silico Prediction of P-glycoprotein Binding: Insights from Molecular Docking Studies. <i>Current Medicinal Chemistry</i> , 2019, 26, 1746-1760.	1.2	18
587	Evaluation of the Effects of <i>Maytenus ilicifolia</i> on the Activities of Cytochrome P450 3A and P-glycoprotein. <i>Current Drug Metabolism</i> , 2020, 21, 281-290.	0.7	6
588	P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice. <i>Drug Metabolism Letters</i> , 2010, 4, 195-201.	0.5	29
589	Cytotoxic, DNA Cleavage and Pharmacokinetic Parameter Study of Substituted Novel Furan C-2 Quinoline Coupled 1, 2, 4-Triazole and Its Analogs. <i>Open Medicinal Chemistry Journal</i> , 2018, 12, 60-72.	0.9	4
590	Membrane transporter proteins: a challenge for CNS drug development. <i>Dialogues in Clinical Neuroscience</i> , 2006, 8, 311-321.	1.8	102
591	In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol. <i>Journal of Bioequivalence & Bioavailability</i> , 2011, 01, .	0.1	18
592	AROMATIC HYDROCARBON RECEPTOR STATUS IN THE METABOLISM OF XENOBIOTICS UNDER NORMAL AND PATHOPHYSIOLOGICAL CONDITIONS. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2004, 148, 3-10.	0.2	35
593	Is the MDR1 C3435T Polymorphism Responsible for Oral Mucositis in Children with Acute Lymphoblastic Leukemia?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 5251-5255.	0.5	19
594	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. <i>Journal of Biomedical Research</i> , 2016, 30, 120-133.	0.7	13
595	Dietary stigmastane-type saponins as promising dual-target directed inhibitors of SARS-CoV-2 proteases: a structure-based screening. <i>RSC Advances</i> , 2021, 11, 33380-33398.	1.7	16
596	Shenjinhuoxue Mixture Attenuates Inflammation, Pain, and Cartilage Degeneration by Inhibiting TLR-4 and NF- κ B Activation in Rats with Osteoarthritis: A Synergistic Combination of Multitarget Active Phytochemicals. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-21.	1.9	11
597	Pharmacological aspects of nephrotoxicity. , 2003, , 657-666.		0
598	Drug-Metabolizing Enzymes and P-Glycoprotein. , 2004, , 43-67.		0
599	Drug Disposition. , 2006, , 123-127.		0
600	Identification of multi-drug resistance gene (MDR1) in equine ileum. <i>Ciencia Rural</i> , 2006, 36, 298-300.	0.3	2
601	Drug Discovery Trends. , 2006, , 1-32.		0

#	ARTICLE	IF	CITATIONS
602	Comparative Analysis of Clinical and Non-Clinical Pharmacokinetic Interactions of Statins with Other Drugs. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2007, 33, 291-300.	0.0	0
604	Chapter 4. Cell Membranes. , 2009, , .		0
605	Dietary Flavonoids as Neuroprotective Agents. <i>Oxidative Stress and Disease</i> , 2009, , .	0.3	0
608	General Principles of Pharmacokinetics and Pharmacodynamics. , 2011, , 1253-1264.		1
610	Clinical Relevance of Drug Interactions in HIV-Infected Patients Receiving Antiretroviral Therapy. , 0, , .		2
611	ABC transporters: circadian rhythms and sex-related differences. <i>Journal of Marmara University Institute of Health Sciences</i> , 2013, , 1.	0.1	0
612	Analysis of Intestinal Transporters. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2013, , 179-199.	0.2	0
613	Effect of Ciprofloxacin on the Plasma Concentration of Doxorubicin, Following Acute and Chronic Dose Protocol in Sprague Dawley Rats. <i>International Journal of Pharmacology</i> , 2013, 10, 69-77.	0.1	1
614	Changes in P-glycoprotein during Treatment with Anti-cancer Drug and its Influence on Pharmacokinetics and Pharmacological Effects. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical)</i> Tj ETQq0 0 0 rg6.0/Overlap 10 Tf 50		0
616	Pharmacotherapy for Mood and Anxiety Disorders. <i>Mental Health and Illness Worldwide</i> , 2016, , 1-27.	0.1	0
617	Editorial: Clopidogrel and the C3435T Single Nucleotide Polymorphism and Breast Cancer Therapies. <i>MOJ Drug Design Development & Therapy</i> , 2017, 1, .	0.1	0
618	Cytotoxic, DNA Cleavage and Pharmacokinetic Parameter Study of Substituted Novel Furan C-2 Quinoline Coupled 1, 2, 4-Triazole and Its Analogs. <i>Open Medicinal Chemistry Journal</i> , 2018, 12, 73-73.	0.9	0
620	Association of C4125A Polymorphisms of MDR-1 gene with childhood acute lymphoblastic leukaemia in Egyptian. <i>Research Journal of Applied Biotechnology</i> , 2019, 5, 80-89.	0.1	0
621	In silico screening of natural products targeting chorismate synthase. <i>Innovaciencia</i> , 2019, 7, 1-9.	0.1	0
622	Nanoparticle Design to Improve Transport Across the Intestinal Barrier. <i>Environmental Chemistry for A Sustainable World</i> , 2020, , 271-315.	0.3	0
623	P-Glycoprotein Efflux Transporters and Its Resistance Its Inhibitors and Therapeutic Aspects. , 0, , .		2
624	Clinically Relevant Interactions with Anti-Infectives on Intensive Care Unitsâ€”A Multicenter Delphi Study. <i>Antibiotics</i> , 2021, 10, 1330.	1.5	2
625	Mollusc-Derived Brominated Indoles for the Selective Inhibition of Cyclooxygenase: A Computational Expedition. <i>Molecules</i> , 2021, 26, 6538.	1.7	4

#	ARTICLE	IF	CITATIONS
626	Governing Issues in Nanoscale Systems and Their Potential for Improving the Therapeutic Application of Phytoconstituents. , 2020, , 571-590.		1
627	Propriedades farmacocinéticas e potencial de inibidores de tirosina quinase de cafeatos fenólicos. Research, Society and Development, 2020, 9, e188911890.	0.0	0
629	Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Xenobiotica, 2006, 36, 1-13.	0.5	9
633	Kratom Alkaloids: Interactions With Enzymes, Receptors, and Cellular Barriers. Frontiers in Pharmacology, 2021, 12, 751656.	1.6	10
634	The Inhibitory Activity of Curcumin on P-Glycoprotein and Its Uptake by and Efflux from LS180 Cells Is Not Affected by Its Galenic Formulation. Antioxidants, 2021, 10, 1826.	2.2	7
635	Potential of phytochemicals from Brassica oleracea targeting S2-domain of SARS-CoV-2 spike glycoproteins: Structural and molecular insights. Journal of Molecular Structure, 2022, 1254, 132369.	1.8	10
636	Molecular Docking of Phytochemicals Targeting GFRs as Therapeutic Sites for Cancer: an In Silico Study. Applied Biochemistry and Biotechnology, 2022, 194, 215-231.	1.4	37
637	Thalidomide-based inhibitor for TNF- α : designing and Insilico evaluation. Future Journal of Pharmaceutical Sciences, 2022, 8, .	1.1	1
638	2-Phenoxyacetamide derivatives as SARS-CoV-2 main protease inhibitor: In silico studies. Results in Chemistry, 2022, 4, 100263.	0.9	6
639	An Overview of Nanotechnologies for Drug Delivery to the Brain. Pharmaceutics, 2022, 14, 224.	2.0	34
640	Psychotropic Medications in Metabolic and Bariatric Surgery: Research Updates and Clinical Considerations. Current Psychiatry Reports, 2022, 24, 89-98.	2.1	10
641	Approaches to minimize the effects of P-glycoprotein in drug transport: A review. Drug Development Research, 2022, 83, 825-841.	1.4	16
642	Impact of Drug Interactions on Major Bleed Rates in Patients Taking Direct Oral Anticoagulants. Journal of Pharmacy Practice, 2023, 36, 600-605.	0.5	2
643	Mesembryanthemum tortuosum L. alkaloids modify anxiety-like behaviour in a zebrafish model. Journal of Ethnopharmacology, 2022, 290, 115068.	2.0	7
644	Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders. Biomedicines, 2022, 10, 398.	1.4	17
645	Cytochrome P450 and P-gp mediated herb-drug interactions of some common Indian herbs. Studies in Natural Products Chemistry, 2022, , 225-258.	0.8	1
646	Reprofiling analysis of FDA approved drugs with upregulated differential expression genes found in hypertension. Informatics in Medicine Unlocked, 2022, 29, 100895.	1.9	1
648	Ivermectin: a mini-review. Clinical Toxicology, 2022, 60, 571-575.	0.8	16

#	ARTICLE	IF	CITATIONS
649	Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 316.	1.1	4
650	Parathyroid Imaging: Past, Present, and Future. <i>Frontiers in Endocrinology</i> , 2021, 12, 760419.	1.5	33
651	Elucidation of the Transport Mechanism of Puerarin and Gastrodin and Their Interaction on the Absorption in a Caco-2 Cell Monolayer Model. <i>Molecules</i> , 2022, 27, 1230.	1.7	1
652	In Vitro and Computational Studies of Perezone and Perezone Angelate as Potential Anti-Glioblastoma Multiforme Agents. <i>Molecules</i> , 2022, 27, 1565.	1.7	2
653	Identification of promising multi-targeting inhibitors of obesity from <i>Vernonia amygdalina</i> through computational analysis. <i>Molecular Diversity</i> , 2023, 27, 1-25.	2.1	17
654	In silico Discovery of potential azole-containing mPGES-1 inhibitors by virtual screening, pharmacophore modeling and molecular dynamics simulations. <i>Structural Chemistry</i> , 0, , 1.	1.0	1
655	Synthesis, antimicrobial, and antitubercular evaluation of new Schiff bases with in silico ADMET and molecular docking studies. <i>European Journal of Chemistry</i> , 2022, 13, 109-116.	0.3	3
656	Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic System. <i>Life</i> , 2022, 12, 485.	1.1	7
657	Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting. <i>Journal of Personalized Medicine</i> , 2022, 12, 526.	1.1	12
658	Uncoupler <i>SYP</i> inducing multidrug resistance of <i>Phytophthora capsici</i> through overexpression of cytochrome <i>P450</i> monooxygenases and <i>P</i> -glycoprotein. <i>Pest Management Science</i> , 2022, 78, 2240-2249.	1.7	6
659	Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites. <i>Frontiers in Pharmacology</i> , 2022, 13, 855000.	1.6	2
660	Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 381, 217-228.	1.3	7
661	Synthesis and structure-activity relationship of <i>L</i> -methionine-coupled 1,3,4-thiadiazole derivatives with activity against influenza virus. <i>Chemical Biology and Drug Design</i> , 2022, 99, 398-415.	1.5	3
662	The Challenge and Importance of Integrating Drug-Nutrient-Genome Interactions in Personalized Cardiovascular Healthcare. <i>Journal of Personalized Medicine</i> , 2022, 12, 513.	1.1	3
663	African derived phytocompounds may interfere with SARS-CoV-2 RNA capping machinery via inhibition of 2'-O-ribose methyltransferase: An in silico perspective. <i>Journal of Molecular Structure</i> , 2022, 1262, 133019.	1.8	3
667	Down-regulation of ABCB1 by collateral sensitivity drugs reverses multidrug resistance and up-regulates enolase I. <i>Journal of Biochemistry</i> , 2022, 172, 37-48.	0.9	5
668	Quantification of vincristine and tariquidar by liquid chromatography-tandem mass spectrometry in mouse whole blood using volumetric absorptive microsampling for pharmacokinetic applications. <i>Journal of Separation Science</i> , 2022, 45, 2508-2519.	1.3	3
669	Polymorphisms. , 2013, , 21-33.e2.		1

#	ARTICLE	IF	CITATIONS
670	Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [18F]MC225 and PET. <i>Journal of Controlled Release</i> , 2022, 347, 500-507.	4.8	7
671	Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor. <i>Cardiology and Therapy</i> , 2022, 11, 407-419.	1.1	10
672	Antimalarial phytochemicals as potential inhibitors of SARS-CoV-2 guanine N7-methyltransferase (nsp) Tj ETQq0 0 0 rBT /Overlock 10 T	2.9	1
673	Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. <i>Thrombosis Research</i> , 2022, 213, S66-S71.	0.8	7
674	Identification of Therapeutic Targets in an Emerging Gastrointestinal Pathogen <i>Campylobacter ureolyticus</i> and Possible Intervention through Natural Products. <i>Antibiotics</i> , 2022, 11, 680.	1.5	5
675	Homology Modeling, de Novo Design of Ligands, and Molecular Docking Identify Potential Inhibitors of <i>Leishmania donovani</i> 24-Sterol Methyltransferase. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	8
676	IMPDB: Indian Medicinal Phytochemical Database Curated for Drug Designing. <i>Journal of Computational Biophysics and Chemistry</i> , 0, , .	1.0	1
677	Design and Synthesis of Some 1,3,4-Thiadiazole Amines: Molecular Docking, in silico ADMET, in vitro Antimicrobials and Antioxidant Studies. <i>Asian Journal of Chemistry</i> , 2022, 34, 2067-2073.	0.1	1
678	Computational evaluation of bioactive compounds from <i>Vitis vinifera</i> as a novel β -catenin inhibitor for cancer treatment. <i>Bulletin of the National Research Centre</i> , 2022, 46, .	0.7	5
679	Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors. <i>JAMA Network Open</i> , 2022, 5, e2219128.	2.8	4
680	TNF- α and IL-1 β Exposure Modulates the Expression and Functionality of <i>P</i> -Glycoprotein in Intestinal and Renal Barriers. <i>Molecular Pharmaceutics</i> , 2022, 19, 2327-2334.	2.3	1
681	Novel Galactopyranoside Esters: Synthesis, Mechanism, In Vitro Antimicrobial Evaluation and Molecular Docking Studies. <i>Molecules</i> , 2022, 27, 4125.	1.7	4
682	Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 29-44.	1.1	2
683	Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation. <i>Molecules</i> , 2022, 27, 4886.	1.7	4
684	Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants—A nationwide cohort study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
685	Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 383, 91-102.	1.3	5
686	Shengmai san-derived compound prescriptions: A review on chemical constituents, pharmacokinetic studies, quality control, and pharmacological properties. <i>Phytomedicine</i> , 2022, 107, 154433.	2.3	9
687	Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1-28.	5.7	5

#	ARTICLE	IF	CITATIONS
688	Structural Design and Synthesis of Novel Cyclic Peptide Inhibitors Targeting Mycobacterium tuberculosis Transcription. <i>Life</i> , 2022, 12, 1333.	1.1	0
689	Influence of MDR1 gene polymorphism (2677G>T) on expression and function of P-glycoprotein at the blood-brain barrier: utilizing novel P-glycoprotein humanized mice with mutation. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 288-292.	0.7	1
690	Pharmacoinformatic study of inhibitory potentials of selected flavonoids against papain-like protease and 3-chymotrypsin-like protease of SARS-CoV-2. <i>Clinical Phytoscience</i> , 2022, 8, .	0.8	1
691	Inhibitory potentials of phytochemicals from <i>Ocimum gratissimum</i> against anti-apoptotic BCL-2 proteins associated with cancer: an integrated computational study. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2022, 9, 588-608.	0.2	0
692	Nanotechnology-Driven Delivery Systems in Inoculation Therapies. <i>Methods in Molecular Biology</i> , 2023, , 39-57.	0.4	0
693	Role of natural P-gp inhibitor in the effective delivery for chemotherapeutic agents. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 367-391.	1.2	11
694	Novel 1,2,4-triazoles derived from Ibuprofen: synthesis and in vitro evaluation of their mPGES-1 inhibitory and antiproliferative activity. <i>Molecular Diversity</i> , 0, , .	2.1	1
695	Computational study of nitro-benzylidene phenazine as dengue virus-2 NS2B-NS3 protease inhibitor. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
697	Lactobacillus acidophilus BIOTECH 1900 decreases the transepithelial mucosal-to-serosal transport of colchicine in an ex vivo non-everted gut sac model. <i>Anais Da Academia Brasileira De Ciencias</i> , 2022, 94, .	0.3	0
698	Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual screening strategy. <i>Computational Toxicology</i> , 2023, 25, 100257.	1.8	3
699	Interspecies and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 221-235.	1.3	3
700	Diyabet Hastalıklarının Tedavisinde Kullanılabilecek Alfa-Amilaz İnhibitörü Olarak Kuersetin ve Umbelliferonun Etkisinin In Silico Kanıtı. <i>Journal of Forestry Faculty of Kastamonu University</i> , 2022, 22, 202-216.	0.1	2
701	Pharmacophore-Oriented Identification of Potential Leads as CCR5 Inhibitors to Block HIV Cellular Entry. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16122.	1.8	0
702	Interaction of a Homologous Series of Amphiphiles with P-glycoprotein in a Membrane Environment: Contributions of Polar and Non-Polar Interactions. <i>Pharmaceutics</i> , 2023, 15, 174.	2.0	3
703	Targeting Leishmania donovani sterol methyltransferase for leads using pharmacophore modeling and computational molecular mechanics studies. <i>Informatics in Medicine Unlocked</i> , 2023, 37, 101162.	1.9	1
704	Acetylcholinesterase inhibition of Alzheimer's disease: Identification of potential phytochemicals and designing more effective derivatives to manage disease condition. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 12532-12544.	2.0	4
705	Pharmaceutical polymers and P-glycoprotein: Current trends and possible outcomes in drug delivery. <i>Materials Today Communications</i> , 2023, 34, 105318.	0.9	7
706	Antiviral effects and tissue exposure of tetrandrine against SARS-CoV-2 infection and COVID-19. <i>MedComm</i> , 2023, 4, .	3.1	1

#	ARTICLE	IF	CITATIONS
707	Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 91, 103-119.	1.1	11
708	Deciphering the therapeutic role of <i>Kigelia africana</i> fruit in erectile dysfunction through metabolite profiling and molecular modelling. <i>Informatics in Medicine Unlocked</i> , 2023, 37, 101190.	1.9	4
709	Identification of natural CTXM-15 inhibitors from aqueous extract of endophytic bacteria <i>Cronobactersakazaki</i> . <i>Brazilian Journal of Microbiology</i> , 0, , .	0.8	0
710	PEG-conjugated bovine haemoglobin enhances efficiency of chemotherapeutic agent doxorubicin with alleviating DOX-induced splenocardiac toxicity in the breast cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2023, 51, 120-130.	1.9	2
711	Simulated Microgravity Alters P-Glycoprotein Efflux Function and Expression via the Wnt/ β -Catenin Signaling Pathway in Rat Intestine and Brain. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5438.	1.8	2
712	In-silico investigation and drug likeliness studies of benzimidazole congeners: The new face of innovation. <i>Informatics in Medicine Unlocked</i> , 2023, 38, 101213.	1.9	3
713	Matrixâ€Metalloproteinase Inhibitory Study of Novel Tetrahydroisoquinolineâ€carboxylates: Design, Synthesis, and Molecular Docking studies.. <i>Chemistry and Biodiversity</i> , 0, , .	1.0	0
714	Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. <i>EClinicalMedicine</i> , 2023, 59, 101955.	3.2	1
715	Imaging blood-brain barrier dysfunction: A state-of-the-art review from a clinical perspective. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	1.7	3
721	In Silico Molecular Docking Study by Using Bio-informatics Database to Fabricate M-Cell Targeting Nanocarrier System for Oral Delivery of Macromolecules. <i>Lecture Notes in Networks and Systems</i> , 2023, , 51-62.	0.5	0
730	Potential of nanostructured lipid carriers in oral delivery of the poorly soluble drugs. <i>Journal of Nanoparticle Research</i> , 2023, 25, .	0.8	2
731	New era of nanoparticles facilitated co-delivery in cancer therapy: two heads are better than one. <i>Journal of Nanoparticle Research</i> , 2023, 25, .	0.8	1
743	Elucidating the Inhibition Mechanism of FDA-Approved Drugs on P-glycoprotein (P-gp) Transporter by Molecular Docking Simulation. <i>Algorithms for Intelligent Systems</i> , 2023, , 221-229.	0.5	1